Newsroom
Sorted by: Latest
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: SANDWELL COMMERCIAL FINANCE NO.2 PLC GBP 14,000,000.00 MATURING: 30-Sep-2037 ISIN: XS0229031280 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 31-Mar-2026 TO 30-Jun-2026 HAS BEEN FIXED AT 9.00 PCT DAY BASIS: ACTUAL/365(PROP) INTEREST PAYABLE VALUE 30-Jun-2026 WILL AMOUNT TO: GBP 750.02 PER GBP 33,412.11 DENOMINATION ...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: SANDWELL COMMERCIAL FINANCE NO.2 PLC GBP 21,700,000.00 MATURING: 30-Sep-2037 ISIN: XS0229031017 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 31-Mar-2026 TO 30-Jun-2026 HAS BEEN FIXED AT 6.15 PCT DAY BASIS: ACTUAL/365(PROP) INTEREST PAYABLE VALUE 30-Jun-2026 WILL AMOUNT TO: GBP 512.61 PER GBP 33,412.11 DENOMINATION ...
-
Organon Canada et Henlius élargissent l’accès aux traitements à base de dénosumab avec le lancement de BILDYOS® (injection de dénosumab) et de TUZEMTY® (injection de dénosumab), des biosimilaires de PROLIA et de XGEVA
KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada et Shanghai Henlius Biotech, Inc. (2696.HK) ont annoncé aujourd’hui que BILDYOS® (injection de dénosumab) 60 mg/1 mL et TUZEMTY® (injection de dénosumab) 120 mg/1,7 mL, des biosimilaires de PROLIA et de XGEVA, respectivement, sont maintenant disponibles au Canada pour toutes les indications des produits de référence. Utilisés dans plusieurs indications, les produits à base de dénosumab sont indiqués dans le traitement de l’ostéoporose...
-
Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA
KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA...
-
Atom Therapeutics Announces First Patient Dosed in China Phase 3 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Gout
HANGZHOU, China & NEWARK, Calif.--(BUSINESS WIRE)--Lingdolinurad lowers the incidence of acute gout flares in phase 2b studies—an advantage that remains challenging for existing gout therapies....
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: NATIONAL WESTMINSTER BANK PLC GBP 750,000,000.00 MATURING: 28-Mar-2029 ISIN: XS2795569925 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 30-Mar-2026 TO 29-Jun-2026 HAS BEEN FIXED AT 4.20 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 29-Jun-2026 WILL AMOUNT TO: GBP 10.46 PER GBP 1,000.00 DENOMINATION ...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: Lloyds Bank Corporate Markets plc USD 32,000,000.00 MATURING: 28-Sep-2026 ISIN: XS2695405915 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 30-Mar-2026 TO 29-Jun-2026 HAS BEEN FIXED AT 4.75 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 29-Jun-2026 WILL AMOUNT TO: USD 2,403.54 PER USD 200,000.00 DENOMINATION ...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: Lloyds Bank Corporate Markets plc USD 30,000,000.00 MATURING: 29-Sep-2026 ISIN: XS2697682826 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 30-Mar-2026 TO 29-Jun-2026 HAS BEEN FIXED AT 4.75 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 29-Jun-2026 WILL AMOUNT TO: USD 2,403.54 PER USD 200,000.00 DENOMINATION ...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: First Abu Dhabi Bank P.J.S.C. USD 22,000,000.00 MATURING: 28-Mar-2029 ISIN: XS2793708566 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 30-Mar-2026 TO 29-Jun-2026 HAS BEEN FIXED AT 4.64 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 29-Jun-2026 WILL AMOUNT TO: USD 2,343.99 PER USD 200,000.00 DENOMINATION ...
-
Omdia: Global Smartphone Average Selling Price to Reach $565 in 2026 as Vendors Prioritize Value Over Volume
LONDON--(BUSINESS WIRE)--Omdia’s latest research shows that the global smartphone market is undergoing a structural shift as rising component costs and geopolitical uncertainty push leading manufacturers to move away from low-cost, high-volume strategies and prioritize premium, high-value portfolios. According to Omdia’s global smartphone forecast, total global smartphone shipments are forecast to contract by 12.2% year-on-year (YoY) in 2026, dropping to 1,093 million units. This represents a d...